CagriSema showed a statistically significant and superior weight loss at week 68 compared to placebo, meeting the trial’s primary aim.
The Phase 3 VENTURA research study, which was assessing aticaprant as an adjunctive treatment for major depressive disorder (aMDD), has been discontinued by Johnson & Johnson because of its lack of effectiveness in the target patient population. No new safety signals were found, and the results verified that aticaprant is […]
The study merely demonstrates a connection rather than proving that painkillers enhance concussion recovery.
In a randomized phase III study, Gazyva®/Gazyvaro® is the only anti-CD20 monoclonal antibody that shows a full renal response benefit.
GUB014295 is a calcitonin and amylin receptor-specific agonist that may be a long-acting amylin analog.
The BEACON-IPF Phase 2b trial, which was assessing bexotegrast in patients with idiopathic pulmonary fibrosis (IPF), has been discontinued by Pliant Therapeutics, Inc. after a predetermined data review and recommendation by the independent Data Safety Monitoring Board (DSMB) of the trial and a secondary review and recommendation by an external […]
Two blockbuster weight loss drugs including Lilly’s Zepbound were in U.S. FDA’s drugs shortage list.
The European Commission is currently taking final action on the application for the use of Jaypirca in patients with relapsed or refractory CLL who have received prior treatment with a BTK inhibitor as a result of this favorable view.
Three blood biomarker categories were evaluated in the study: phosphorylated tau 181, glial acidic proteins, and neurofilament light chain proteins.
American pharma giant Merck’s application for KEYTRUDA® (pembrolizumab) receives US FDA’s priority review acceptance. Acceptance based on results from the KEYNOTE-689 trial. This is the first Phase 3 study to show a notable increase in event-free survival in the early stages of head and neck squamous cell carcinoma when using […]
